NCT00459875

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Phase II Study of Sunitinib in Patients With Metastatic Papillary Renal Cell Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with locally recurrent or metastatic kidney cancer.

Detailed description

OBJECTIVES: Primary * Determine the efficacy of sunitinib malate in patients with locally recurrent or metastatic papillary renal cell carcinoma. OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 28 days and every 2 months thereafter.

Conditions

• Kidney Cancer

Interventions

Type	Name	Description
DRUG	sunitinib malate

Timeline

• Start date: 2007-03-01
• Primary completion: 2010-11-01
• Completion: 2010-11-01
• First posted: 2007-04-13
• Last updated: 2015-11-26
• Results posted: 2015-11-26

Locations

1 site across 1 country: United States